Deal covers production of fibrinogen.

Crucell entered into a nonexclusive STAR® research license agreement with ProFibrix covering the production of specific forms of human fibrinogen.

According to Crucell, STAR technology is a production method that is particularly useful for the production of recombinant human antibodies and proteins.

Previous articleLilly Gains Access to Ambrx’ Protein Optimization Technology
Next articleAmbrx Allies with Merck & Co. in Type 2 Diabetes Drug Discovery Collaboration